This proposal combines a consolidated prognostic clinical model with the main sources of biological variation among the DLBCL cases—COO and MYC/BCL2 expression—in a risk model that produces a patient‐specific risk estimate based on a firmly established molecular approach that can be used with paraffin‐embedded tissues. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.